Loading stock data…
ZTS
$112.54-0.14 (-0.12%)
Market ClosedLast close May 5
Zoetis Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Zoetis Inc. in the Healthcare sector is trading at $112.54. The stock is currently near its 52-week low of $111.27, remaining 13.9% below its 200-day moving average. Technical signals show neutral RSI of 32 and bearish MACD signal, explaining why ZTS maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 32) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$112.54
Potential Upside
74.7%
Whystock Fair Value$196.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus17 analysts
Buy
Mean target$148.88+32.3%
Range$127.00 – $190.00
Fundamentals
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the Uni...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$48.99B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
19.28
Beta
Defensive asset. Lower volatility than the S&P 500.
0.97
Div Yield
Strong income play. Yield provides a meaningful total return floor.
183.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
78.41%
Volume
Today's trading volume
2.73M
Recent News
Five Dividend Growers Trading at Double-Digit Discounts Despite Strong Fundamentals
On a recent Morningstar Investing Insights segment unveiling the 2026 class of exceptional dividend growers, the host offered one caveat worth the entire show: “Valuation was not a component in this screen whatsoever.” A stock can clear the bar for double-digit dividend raises, a narrow or wide moat, and low or medium uncertainty, and still ... Five Dividend Growers Trading at Double-Digit Discounts Despite Strong Fundamentals
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
A Look At Zoetis (ZTS) Valuation As Earnings Optimism And AI Diagnostics News Draw Fresh Focus
Why Zoetis Stock Is Back in Focus Zoetis (ZTS) is drawing fresh attention as investors weigh upbeat expectations for its upcoming first quarter 2026 earnings, recent product news around its Vetscan OptiCell platform, and supportive analyst commentary. See our latest analysis for Zoetis. Despite upbeat expectations around the May 7 earnings release and fresh attention on its AI-powered diagnostics, Zoetis’ recent share price performance has been weak. The 30 day share price return shows a...